RxDoctor Payments DataLook up a doctor →

Senthil Thambidorai, MD

Clinical Cardiac Electrophysiology · Fort Worth, TXNPI 1700968740

Payments from drug & device makers

$317,124in general payments, 2019–2025

Across 1,377 payments — averaging $230.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$120K
  • Janssen Research & Development, LLC$77K
  • Cardiva Medical, Inc.$37K
  • Impulse Dynamics (USA) Inc.$21K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$18K
  • Sanofi-aventis U.S. LLC$17K
  • plus $27K from 22 others
$850in research payments, 2019–2025

Across 5 payments — averaging $169.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotronik Inc.$820
  • Abiomed$30

What the payments were for

  • Consulting fees$30,39330%
  • Speaking & faculty fees$31,44331%
  • Travel & lodging$8,9839%
  • Food & beverage$29,50829%
  • Education$1060%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$317,124 in reported general payments places this provider in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$361,146
Medicare patients
523
Services billed
2,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban265$293,620
XareltoRivaroxaban40$43,098
EntrestoSacubitril/Valsartan25$30,505
Dofetilide34$5,583
Metoprolol Succinate177$2,275
Flecainide Acetate39$1,664
SotalolSotalol Hcl28$694
Diltiazem 24hr Er (Cd)Diltiazem Hcl17$504
Potassium Chloride17$471
Metoprolol Tartrate69$467
Diltiazem Hcl21$411
Furosemide51$278
Carvedilol42$270
Amiodarone Hcl27$263
Pravastatin Sodium11$177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$293,620265 claims
Johnson & JohnsonXarelto$60$43,09840 claims
NovartisEntresto$36$30,50525 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →